Website www.julphar.net Headquarters Ras al-Khaimah Number of employees 2,900 | Revenue 1.43 billion AED (2014) Founded 30 March 1980 Net income 234.7 million AED (2014) | |
 | ||
Key people Sheikh Faisal bin Saqr Al Qasimi Chairman of the BoardDr. Ayman Ahmed Sahli CEO Products Julphar manufacture and sell more than 213 products Subsidiaries Mena Cool F.Z.E, Julphar Pharmacies Profiles | ||
Julphar (Gulf Pharmaceutical Industries) is a public shareholding pharmaceutical company based in Diqdaqah, Ras Al Khaimah, United Arab Emirates. It was established in 1980 under Sheikh Saqr bin Mohammad al-Qassimi, the late ruler of Ras Al Khaimah and currently produces and distributes pharmaceutical products across five continents. Julphar produces therapeutic products which target a large range of pharmaceutical segments including consumer, endocrinology, antibiotics, cardiovascular, women's health, dermatology and gastroenterology.
Contents
- Diretube news julphar to build africa s largest injectable medicine plant
- Operations
- Board of Directors
- References
Diretube news julphar to build africa s largest injectable medicine plant
Operations
One of Julphar’s strategic products include Moist Exposure Burn Ointment (MEBO), a common product used for burns. The success of MEBO led to the creation of MEBO Scar, an ointment which was developed specifically by Julphar for the treatment of scars both old and new, and is used to restore the health of traumatized skin. MEBO Scar assists patients with both functional and cosmetic problems caused by scarring.
In 2012, Julphar will become the only company in the Middle East and North Africa Region to locally produce Recombinant DNA(r-DNA), the raw material used to make insulin. Julphar Diabetes—a division of Julphar that will manage the manufacturing and commercialization the company’s diabetes products—has the facility to produce approximately 40 million vials of insulin per year. In 2011, Julphar signed a partnership with International Diabetes Federation (IDF). Diabetes rates in the MENA are amongst the highest in the world. IDF estimates that in 2011, 32.6 million people are living with diabetes in the region, and this is expected to increase by over 80% by 2030.
Julphar maintains a network of eleven manufacturing plants based in the UAE, with plans to open additional facilities in strategic countries such as Kingdom of Saudi Arabia, Ethiopia and Algeria. In 2011, Julphar signed an agreement with Saudi-based Cigalah Group, to build an independent manufacturing facility in the western region of KSA, in a project worth US$40 million.
In 2011, Julphar crossed AED 1billion in sales, an 11.3% growth from 2010. In January 2013, Julphar launched its first international facility in Addis Ababa Ethiopia. This facility has the capacity to produce 25 million bottles, 50 million tablets and 170 million capsules per year.